Gennex Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Gennex Laboratories Ltd reported a 44.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 41.0%.
• Its expenses for the quarter were up by 60.0% QoQ and 43.3% YoY.
• The net profit decreased 25.7% QoQ and increased 45.3% YoY.
• The earnings per share (EPS) of Gennex Laboratories Ltd stood at 0.16 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gennex Laboratories Ltd is a company engaged in the pharmaceutical industry. As a player in this sector, it primarily focuses on the manufacture and distribution of pharmaceutical products. The company is known for producing a wide range of active pharmaceutical ingredients (APIs), catering to both domestic and international markets. In recent developments, the pharmaceutical industry has been experiencing advancements in drug development and increased demand for healthcare products, which could be relevant to the company's operations. However, specific recent developments pertaining to Gennex Laboratories Ltd are not available in the provided data.

Revenue

In the fourth quarter of the fiscal year 2026, Gennex Laboratories Ltd reported a total income of ₹62.27 crores. This represents a significant increase of 44.9% compared to the previous quarter, Q3FY26, where the total income was ₹42.96 crores. Furthermore, on a year-over-year basis, the total income rose by 41.0% from ₹44.16 crores in Q4FY25. This data highlights a strong upward trend in revenue generation for the company over both the quarterly and yearly periods.

Profitability

For Q4FY26, Gennex Laboratories Ltd reported a profit before tax of ₹4.67 crores, which is a decline of 29.7% from the previous quarter, Q3FY26, where the profit before tax was ₹6.64 crores. However, when compared to the same quarter in the previous year, Q4FY25, the profit before tax increased by 18.2% from ₹3.95 crores. The profit after tax for Q4FY26 stood at ₹4.46 crores, showing a decrease of 25.7% from Q3FY26's ₹6.00 crores but a significant rise of 45.3% from ₹3.07 crores in Q4FY25. Earnings per share in Q4FY26 were ₹0.16, down 23.8% from ₹0.21 in Q3FY26, yet up 23.1% from ₹0.13 in Q4FY25.

Operating Metrics

The total expenses for Gennex Laboratories Ltd in Q4FY26 were ₹57.61 crores, marking a 60.0% increase from the previous quarter's expenses of ₹36.01 crores. On a year-over-year basis, total expenses rose by 43.3% from ₹40.20 crores in Q4FY25. The tax expense for Q4FY26 was ₹0.21 crores, which is a reduction of 67.7% from Q3FY26's ₹0.65 crores and a decline of 76.1% from ₹0.88 crores in Q4FY25. These figures indicate significant changes in the company's operating cost structure over the analyzed periods.